伐诺司林二盐酸盐结构式
|
常用名 | 伐诺司林二盐酸盐 | 英文名 | Vanoxerine dihydrochloride |
---|---|---|---|---|
CAS号 | 67469-78-7 | 分子量 | 523.485 | |
密度 | N/A | 沸点 | 542.7ºC at 760 mmHg | |
分子式 | C28H34Cl2F2N2O | 熔点 | 221 °C | |
MSDS | 美版 | 闪点 | 282ºC |
伐诺司林二盐酸盐用途Vanoxerine dihydrochloride是有效,选择性的多巴胺再摄取抑制剂。 |
中文名 | 伐诺司林二盐酸盐 |
---|---|
英文名 | vanoxerine dihydrochloride |
中文别名 | 1-(2-[双(4-氟苯基)甲氧基]乙基)-4-(3-苯基丙基)哌嗪二盐酸盐 | 伐洛司林二盐酸盐 |
英文别名 | 更多 |
描述 | Vanoxerine dihydrochloride是有效,选择性的多巴胺再摄取抑制剂。 |
---|---|
相关类别 | |
参考文献 |
沸点 | 542.7ºC at 760 mmHg |
---|---|
熔点 | 221 °C |
分子式 | C28H34Cl2F2N2O |
分子量 | 523.485 |
闪点 | 282ºC |
精确质量 | 522.201599 |
PSA | 15.71000 |
LogP | 6.80100 |
外观性状 | 白色固体 |
储存条件 | 存放在密封容器内,并放在阴凉,干燥处。储存的地方必须远离氧化剂。 |
稳定性 | 远离氧化物。 |
分子结构 | 1、 摩尔折射率:128.60 2、 摩尔体积(m3/mol):396.7 3、 等张比容(90.2K):1008.1 4、 表面张力(dyne/cm):41.6 5、 极化率(10-24cm3):50.98 |
计算化学 | 1.疏水参数计算参考值(XlogP):无 2.氢键供体数量:2 3.氢键受体数量:5 4.可旋转化学键数量:10 5.互变异构体数量:无 6.拓扑分子极性表面积15.7 7.重原子数量:35 8.表面电荷:0 9.复杂度:498 10.同位素原子数量:0 11.确定原子立构中心数量:0 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:3 |
更多 | 1. 性状:固体。 2. 密度(g/mL,25/4℃):未确定 3. 相对蒸汽密度(g/mL,空气=1):未确定 4. 熔点(ºC):未确定 5. 沸点(ºC,常压):未确定 6. 沸点(ºC,5.2kPa):未确定 7. 折射率:未确定 8. 闪点(ºC):未确定 9. 比旋光度(º):未确定 10. 自燃点或引燃温度(ºC):未确定 11. 蒸气压(kPa,25ºC):未确定 12. 饱和蒸气压(kPa,60ºC):未确定 13. 燃烧热(KJ/mol):未确定 14. 临界温度(ºC):未确定 15. 临界压力(KPa):未确定 16. 油水(辛醇/水)分配系数的对数值:未确定 17. 爆炸上限(%,V/V):未确定 18. 爆炸下限(%,V/V):未确定 19. 溶解性:未确定 。 |
个人防护装备 | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
---|---|
危险品运输编码 | NONH for all modes of transport |
~60% 伐诺司林二盐酸盐 67469-78-7 |
文献:Van Der Zee; Koger; Gootjes; Hespe European Journal of Medicinal Chemistry, 1980 , vol. 15, # 4 p. 363 - 370 |
~% 伐诺司林二盐酸盐 67469-78-7 |
文献:Ironside, Michael D.; Sugathapala, Priyantha M.; Robertson, Jerod; Darey, Mark C.P.; Zhang, Jianzhong Organic Process Research and Development, 2002 , vol. 6, # 5 p. 621 - 627 |
~% 伐诺司林二盐酸盐 67469-78-7 |
文献:Organic Process Research and Development, , vol. 6, # 5 p. 621 - 627 |
~% 伐诺司林二盐酸盐 67469-78-7 |
文献:Organic Process Research and Development, , vol. 6, # 5 p. 621 - 627 |
~% 伐诺司林二盐酸盐 67469-78-7 |
文献:Organic Process Research and Development, , vol. 6, # 5 p. 621 - 627 |
~% 伐诺司林二盐酸盐 67469-78-7 |
文献:Organic Process Research and Development, , vol. 6, # 5 p. 621 - 627 |
Serotonin at the level of the amygdala and orbitofrontal cortex modulates distinct aspects of positive emotion in primates.
Int. J. Neuropsychopharmacol. , 1-15, (2011) Impaired top-down regulation of the amygdala, and its modulation by serotonin (5-HT), is strongly implicated in the dysregulation of negative emotion that characterizes a number of affective disorders... |
|
Dopamine uptake inhibitors but not dopamine releasers induce greater increases in motor behavior and extracellular dopamine in adolescent rats than in adult male rats.
J. Pharmacol. Exp. Ther. 335(1) , 124-32, (2010) Most life-long drug addiction begins during adolescence. Important structural and functional changes in brain occur during adolescence and developmental differences in forebrain dopamine systems could... |
|
Differential effects of dopamine transporter inhibitors in the rodent Iowa gambling task: relevance to mania.
Psychopharmacology 225(3) , 661-74, (2013) The Iowa Gambling Task (IGT) can be used to quantify impulsive and risky choice behaviors in psychiatric patients, e.g., bipolar disorder (BD) sufferers. Although developing treatments for these behav... |
1-{2-[Bis(4-fluorophenyl)methoxy]ethyl}-4-(3-phenylpropyl)piperazine dihydrochloride |
Vanoxerine dihydrochloride |
Piperazine, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)-, hydrochloride (1:2) |
MFCD00055193 |
1-[2-[bis(4-fluorophenyl)methoxy]-ethyl]-4-[3-phenylpropyl]piperazine dihydrochloride |
1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine,dihydrochloride |
Vanoxerine hydrochloride |
Vanoxerine (dihydrochloride) |